Donor immune cells for blood cancer after transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing a new way to treat blood cancers that have come back after a stem cell transplant and haven't responded to standard donor cell therapy. The treatment uses special immune cells that are modified to avoid attacking the body, which may help fight the cancer without causing graft-versus-host disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have a blood cancer or blood disorder such as leukemia, myelodysplasia, myeloproliferative disorder, CLL, myeloma, or lymphoma.
- You have had a stem cell transplant (using donor stem cells) and your disease has come back after the transplant.
- Standard donor cell therapy (donor lymphocyte infusion) has not worked for you or only partially worked.
- You do not have active graft-versus-host disease (GVHD) requiring treatment, and your organs (kidneys and liver) are functioning reasonably well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether giving donor immune cells (DLI) that have been “depleted” of a specific marker (CD45RA) can lower the chance of the leukemia/lymphoma coming back after a half-matched stem cell transplant. It’s meant to be preventive, not treatment for an active relapse.
This early-phase study tests a modified immune-cell treatment given after a haploidentical stem cell transplant (using a half-matched donor). It aims to reduce the immune attack complications while still helping prevent or control blood cancer return.
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
This study tests whether giving extra immune cells (called DLI) before or after a stem cell transplant can help prevent or treat leukemia relapse. These cells come from the same family member who donated your transplant, and the study also asks the donor to do some exercise sessions beforehand.
This trial tests whether specially prepared donor immune cells can fight stubborn viral infections that did not get better with standard treatment. It is for people who have had a stem cell transplant and are still struggling with viruses like CMV, EBV, or others.
This trial tests giving special immune cells to patients who had a stem cell transplant and are at high risk for viral infections. The cells may help prevent or fight infections like CMV and EBV after transplant.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.